As Alex­ion fields ap­pli­ca­tions for ALXN1210, a ri­val aims for the crown with head-to-head PhI­II; No­vo hands NBE €20M

→ Alex­ion $ALXN has filed for a Eu­ro­pean ap­proval for ALXN1210, one in a se­ries of ap­pli­ca­tions that fol­lowed the re­cent ap­pli­ca­tion in the US. De­signed to suc­ceed their fran­chise drug Soliris, the drug has some ad­van­tages in treat­ing PNH, but didn’t prove su­pe­ri­or in piv­otal tests. In­ter­est­ing­ly, ear­li­er this week one of Alex­ion’s ri­vals, Apel­lis $APLS, start­ed a head-to-head Phase III study com­par­ing its APL-2 with Soliris, one of the world’s most ex­pen­sive ther­a­pies. Apel­lis CEO Cedric Fran­cois not­ed: “We be­lieve there’s an un­met med­ical need to bring pa­tients with PNH a bet­ter treat­ment op­tion that will pro­vide broad hema­to­log­i­cal cor­rec­tion and bet­ter qual­i­ty of life than the cur­rent stan­dard of care.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER